Anne Phillips, MD, leads an integrated drug development, medical, regulatory, and safety team of more than 750 people, and plays a key role in advancing Novo Nordisk's diabetes and biopharmaceuticals clinical development pipelines.
As Senior Vice President, Clinical, Medical & Regulatory Affairs, Dr. Phillips is responsible for the efficient development and delivery of compounds in clinical trials, including product lifestyle and in-licensed compounds.
Before joining Novo Nordisk, she served as a Vice President of Clinical Development at GlaxoSmithKline, leading diverse global and regional clinical teams supporting metabolic, diabetes and oncology medicines, as well as drug discovery. While there, she provided clinical leadership and partnership in the management of one of the company’s largest medicines and formulated a deep level of understanding of the needs of both patients and healthcare professionals.
Dr. Phillips is active in community service and has served on a multitude of boards. She has also been recognized for her efforts in the areas of education and health. Dr. Phillips received the Outstanding Teacher Award at Wellesley Central Hospital/St. Michael’s Hospital for undergraduate and postgraduate excellence in teaching. For her contribution in the areas of HIV and AIDS, she won a humanitarian award for sustained excellence from an African community.
Prior to working in the pharmaceutical industry, Dr. Phillips was Associate Professor and Chief of Infectious Diseases at Wellesley Central Hospital at the University of Toronto.
She is a Fellow of The Royal College of Physicians and Surgeons of Canada and received her MD from the University of Toronto, and holds an Honors Bachelor of Sciences degree in Zoology from the University of Western Ontario.